While neuroinflammation plays an important role in neurodegenerative diseases such as Alzheimer’s, it is also strongly present in disorders secondary to concussion. With this in mind, and based on evidence of the anti-inflammatory effects of its triphoton emission device, REGEnLIFE has extended the application of its solution to sports-related concussions. The aim? To reduce neural inflammation following violent impact on brain regions.

“Initial results are promising. A larger-scale study will confirm the efficacy of the solution developed by REGEnLIFE, and thus demonstrate that it is one of the treatments available to amateur and high-level sportsmen and women, both to improve post-concussion disorders and, in the event of repeated concussions, to prevent the development of chronic post-traumatic encephalopathy”, says Professor Jacques Touchon, neurologist and Chairman of REGEnLIFE’s Scientific Advisory Board.

The first investigation in this field, Recovery, is a pilot study – prospective, comparative, single-blind, randomized, single-center – conducted at the George Pompidou European Hospital in Paris. Launched at the end of 2022, the study assessed the safety, ease of use and performance of the REGEnLIFE system in 52 rugby players with acute concussion, when applied less than 72 hours after shock. The players were treated, using a specially designed helmet, over two 20-minute therapy sessions seven days apart, and then monitored for 45 days.